This invention describes a microRNA gene expression profile in prostate cancers that correlates with androgen responsiveness. Most prostate cancers are androgen sensitive and can be treated with anti-androgen therapies. Tumors non-responsive to anti-androgen therapy are more aggressive and need alternative therapeutic interventions. Additionally, the microRNAs discovered can also be potential targets for developing new prostate cancer drugs.

Applications:
MicroRNA expression profile can help physicians take informed treatment action on an individual basis.

Advantages:
In vitro proof-of-concept data available.

U.S. Provisional Application No. 60/906,742 filed 12 Mar 2007 (HHS Reference No. E-142-2007/0-US-01)

PCT Application No. PCT/US2008/003346 filed 12 Mar 2008 (HHS Reference No. E-142-2007/0-PCT-02)

Inventors:
Dr. Chang Hee Kim et al. (NCI)

Licensees Sought:
Available for exclusive and non-exclusive licensing.

Collaborative Research Opportunity:
The NCI/SAIC-Frederick, Advanced Technology Program, Laboratory for Molecular Technology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize microRNA diagnostic markers in cancer. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.